Open AccessHematopoietic Stem Cell Transplantation for Fanconi Anemia: A Single Center Experience from India
Author(s) -
Divya Doval,
Deepak Choudhary,
Sanjeev Sharma,
Vipin Khandelwal,
Meet Kumar,
Anil Handoo,
Rasika Setia
Publication year - 2020
Publication title -
indian journal of hematology and blood transfusion/indian journal of hematology and blood transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.213
H-Index - 15
eISSN - 0974-0449
pISSN - 0971-4502
DOI - 10.1007/s12288-020-01254-3
Subject(s) - medicine , fanconi anemia , fludarabine , hematopoietic stem cell transplantation , hematology , savior sibling , transplantation , anemia , single center , bone marrow failure , surgery , pediatrics , stem cell , haematopoiesis , chemotherapy , cyclophosphamide , biochemistry , chemistry , dna repair , gene , genetics , biology
Hematopoietic stem cell transplantation (HSCT) is the only treatment option for the hematological manifestations of Fanconi anemia (FA). Fludarabine based reduced intensity conditioning regimens have helped in improving outcomes significantly in FA patients. We retrospectively analyzed the outcomes of FA patients who underwent allogeneic HSCT at BLK Superspeciality Hospital, New Delhi from June 2011 to September 2019. Twenty FA patients underwent 23 transplants at our center. Overall survival and disease free survival were 65% and 50%, respectively at a median of 23 months. Overall mortality was 30%. HSCT for FA is a feasible option even in developing countries although children present late to transplant centers after multiple transfusions and infections.